Skip to main content

Advertisement

Table 2 ORs and 95% CIs for CCL and breast cancer risk among participants with BBD

From: Columnar cell lesions and subsequent breast cancer risk: a nested case-control study

  Cases Controls OR (95%CI)* OR (95%CI)**
CCL status     
   No CCL 254 1,158 1.0 (reference) 1.0 (reference)
   CCL 140 448 1.44 (1.14, 1.83) 1.37 (1.06, 1.76)
CCL status, adjusted for BBD histologic category     
   No CCL 254 1,158 1.0 (reference) 1.0 (reference)
   CCL 140 448 1.20 (0.94, 1.54) 1.16 (0.89, 1.50)
Jointly classified BBD/CCL histologic category     
   Nonproliferative, no CCL 80 518 1.0 (reference) 1.0 (reference)
   Nonproliferative, CCL 19 93 1.33 (0.77, 2.29) 1.24 (0.69, 2.22)
   Proliferative without atypia, no CCL 125 558 1.46 (1.08, 1.99) 1.38 (1.00, 1.91)
   Proliferative without atypia, CCL 74 277 1.81 (1.27, 2.58) 1.63 (1.12, 2.38)
   Atypical hyperplasia, no CCL 49 82 4.26 (2.75, 6.59) 4.04 (2.57, 6.36)
   Atypical hyperplasia, CCL 47 78 4.37 (2.81, 6.81) 4.20 (2.63, 6.70)
  1. OR indicates odds ratio; 95% CI, 95% confidence interval.
  2. *Adjusted for age, year of BBD diagnosis, and time since BBD biopsy.
  3. **Adjusted for the above-mentioned factors and body mass index at age 18, weight change between age 18 and diagnosis/index date, family history of breast cancer, postmenopausal hormone use, and jointly classified parity/age at first birth.